Charles River Abandons WuXi PharmaTech Just Days Before Crucial Shareholder Votes On Planned Merger
This article was originally published in PharmAsia News
Executive Summary
BEIJING - Like a prospective bride who has been jilted at the very last moment by a suitor, Shanghai's WuXi PharmaTech has been abandoned by the Massachusetts-headquartered Charles River Laboratories on the eve of the two contract research organizations' merger
You may also be interested in...
Asia Spotlight: WuXi AppTec Senior VP Richard Soll On China’s Pharma Evolution
Soll talks about the transition of China’s top CRO from a preclinical play to an integrated services provider for innovative drug development.
WuXi AppTec SVP Richard Soll On China’s Pharma Evolution: An Interview With PharmAsia News
Soll talks about the transition of China’s top CRO from a preclinical play to an integrated services provider for innovative drug development.
WuXi Forms JV With PRA To Expand Clinical Services In China
WuXi PharmaTech forms a joint venture with U.S. contract research organization PRA to grow its clinical capabilities in China; the move expands PRA’s reach to 16 Chinese cities.